A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects
NCT01616277 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 86
Last updated 2014-09-25
Summary
The purpose of this study is to determine if the study drug, PF-06252616 is safe and well tolerated when given to adult healthy volunteers.
Conditions
- Healthy
Interventions
- BIOLOGICAL
-
PF-06252616
1.0 milligram per kilogram of PF-06252616, IV infusion, single dose
- DRUG
-
Placebo for PF-06252616, IV infusion, single dose
- BIOLOGICAL
-
PF-06252616
3.0 milligram per kilogram of PF-06252616, IV infusion, single dose
- DRUG
-
Placebo for PF-06252616, IV infusion, single dose
- BIOLOGICAL
-
PF-06252161
10.0 milligram per kilogram of PF-06252616, IV infusion, single dose
- DRUG
-
Placebo for PF-06252616, IV infusion, single dose
- BIOLOGICAL
-
PF-06252616
3.0 milligram per kilogram of PF-06252616, Subcutaneous injection, single dose
- DRUG
-
Placebo for PF-06252616, Subcutaneous injection, single dose
- BIOLOGICAL
-
PF-06252616
10.0 miligram per kilogram of PF-06252616, IV infusion, repeat dose
- DRUG
-
Placebo for PF-06252616, IV infusion, repeat dose
- BIOLOGICAL
-
PF-06252616
20.0 milligram per kilogram of PF-06252616, IV infusion, single dose
- DRUG
-
Placebo for PF-06252616, IV infusion, single dose
- BIOLOGICAL
-
PF-06252616
40.0 milligram per kilogram of PF-06252616, IV infusion, single dose
- DRUG
-
Placebo for PF-06252616, IV infusion, single dose
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 64 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2012-06-30
- Primary Completion
- 2014-08-31
- Completion
- 2014-08-31
Countries
- United States
Study Locations
More Related Trials
-
A Clinical Study Evaluating The Safety And Tolerability Of PF-04427429 In Healthy Adult Volunteers. The Pharmacokinetics And Pharmacodynamics Of PF-04427429 Will Also Be Investigated
NCT01165723 ·Status: COMPLETED ·Phase: PHASE1
-
A Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Multiple Oral Doses Of PF-04895162
NCT01691274 ·Status: COMPLETED ·Phase: PHASE1
-
Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects
NCT02871037 ·Status: COMPLETED ·Phase: PHASE1
-
A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Oral Doses Of PF-06273340
NCT01601834 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859
NCT02766621 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I Trial to Investigate the Safety and Tolerability of PF-06412562
NCT01914796 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Learn How Different Amounts and Forms of the Study Medicine Called PF-06414300 Act in Healthy Adults
NCT06659250 ·Status: COMPLETED ·Phase: PHASE1
-
A Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03049423 In Healthy Adult Volunteers And Healthy Older Volunteers
NCT01161069 ·Status: COMPLETED ·Phase: PHASE1
-
Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Oral Pf-06650833 In Healthy Subjects
NCT02485769 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Comparing PF-06273340 Immediate Release Tablet, PF-06273340 Modified Release Tablets To PF-06273340 Oral Solution In The Fasted State. This Study Will Also Compare PF-06273340 Modified Release Tablets In Fasted And Fed State
NCT01706796 ·Status: COMPLETED ·Phase: PHASE1
-
Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects
NCT01794364 ·Status: COMPLETED ·Phase: PHASE1
-
A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.
NCT01169714 ·Status: COMPLETED ·Phase: PHASE1
-
A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649
NCT02151617 ·Status: COMPLETED ·Phase: PHASE1
-
A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Following A Single Dose Of PF-04995274 In Healthy Adult Volunteers
NCT01091272 ·Status: COMPLETED ·Phase: PHASE1
-
OPEN LABEL, 2-PERIOD STUDY, TO COMPARE BIO-AVAILABILITY OF 2 DIFFERENT FORMULATIONS OF PF-05221304 IN HEALTHY ADULTS
NCT03871439 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy Adults
NCT06003777 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate Safety and Tolerability of Single Ascending Doses of Multiple Formulations of PF-06650833 in Healthy Subjects Under Fasted and Fed Conditions
NCT02224651 ·Status: COMPLETED ·Phase: PHASE1
-
First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects
NCT03309241 ·Status: COMPLETED ·Phase: PHASE1
-
A Single Ascending Dose Study To Evaluate Safety And Pharmacokinetics Of Compound PF-06648671 In Healthy Subjects
NCT02316756 ·Status: COMPLETED ·Phase: PHASE1
-
Single Dose Study to Assess the Safety, Tolerability and Pharmacokinetics(PK) of PF-06865571
NCT03092232 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Learn How Different Forms of the Study Medicine Called PF-07976016 Are Taken Up Into the Blood in Healthy Adults
NCT06670170 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)
NCT01934738 ·Status: COMPLETED ·Phase: PHASE1
-
Single Dose Study of PF-05230907 in Healthy Japanese Subjects
NCT02537002 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04629991 in Healthy Volunteers
NCT00797342 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Repeat Doses of PF-06372865 in Healthy Subjects
NCT03351751 ·Status: COMPLETED ·Phase: PHASE1